Abstract Number: 2075 • ACR Convergence 2022
Risk of Bloodstream Infection in Patients with Systemic Lupus Erythematosus Exposed to Prolonged Moderate to High Dose Glucocorticoids
Background/Purpose: This study aimed to investigate the incidence and risk factors of bloodstream infection (BSI) in patients with systemic lupus erythematosus (SLE) receiving moderate-to-high dose…Abstract Number: 0467 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…Abstract Number: 1068 • ACR Convergence 2022
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
Background/Purpose: The gastrointestinal tract is commonly affected in systemic sclerosis (SSc). Prior studies have reported an association between higher levels of anti-vinculin antibodies and gastrointestinal…Abstract Number: 1443 • ACR Convergence 2022
Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features
Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated.…Abstract Number: 1853 • ACR Convergence 2022
A Comparitive Study of NLRP3- and NLRP12-autoinflammatory Disease
Background/Purpose: NLRP3-associated autoinflammatoy disease (NLRP3-AID) and NLRP12-AID are rare autosomal dominant diseases. FACS1(familial cold autoinflammatory syndrome type 1), a subset of NLRP3-AID, is thought to…Abstract Number: 2076 • ACR Convergence 2022
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the…Abstract Number: 0469 • ACR Convergence 2022
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
Background/Purpose: Corticosteroids are the cornerstone of therapy in patients with giant cell arteritis (GCA). Tapering regiments vary considerably in both dose and duration, while relapses…Abstract Number: 1070 • ACR Convergence 2022
Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis
Background/Purpose: Assessment of disease burden is crucial in the management of systemic sclerosis (SSc). The patient global assessment (PatGA) is a patient self-reported measure widely…Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…Abstract Number: 1858 • ACR Convergence 2022
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…Abstract Number: 2088 • ACR Convergence 2022
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
Background/Purpose: The treatment target for systemic lupus erythematosus (SLE) is remission or, if this cannot be reached, the lowest disease activity achievable with the least…Abstract Number: 0080 • ACR Convergence 2022
Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
Background/Purpose: Biologic and targeted synthetic disease modifying antirheumatic drugs (bDMARD and tsDMARD) are immunosuppressant, and there have been concerns that they might impact tumor immunity…Abstract Number: 0514 • ACR Convergence 2022
Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen
Background/Purpose: There have been no published studies comparing renal outcomes of youth with proliferative lupus nephritis (LN) treated with the lower-dose EuroLupus (EL) cyclophosphamide (CYC)…Abstract Number: 1071 • ACR Convergence 2022
Trimethoprim Sulfamethoxazole Use in Patients with Granulomatosis with Polyangiitis Treated with Rituximab
Background/Purpose: Trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis is recommended during induction of ANCA-associated vasculitis (AAV) to prevent pneumocystis jirovecii pneumonia (PJP), and may also reduce the risk…Abstract Number: 1484 • ACR Convergence 2022
Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients
Background/Purpose: Lupus erythematosus (LE) patients are at heightened risk of clinical events, chiefly heart attacks and strokes, caused by ASCVD. To address this problem, we…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 28
- Next Page »